Hi Billy,
Two quick point about the Finnish study. If you look at the model there was little to no PD1 response (ie the model was very immune resistant).
Secondly, the oncolytic viruses don’t produce oncolysis in these mouse models. The response you see is entirely from the immune response. The oncolysis response would be in addition to that shown on the graphs. There are other studies from this and other companies just looking at the “naked” viruses. Many with all sorts of added transgenes to increase the local immune activation. All now being used in conjunction with CPI’s.
This is also why T-VEC is now back in trials in combination with CPI’s.
I have not read all the posts so there are probably other questions. If I have time this weekend I will have a look.
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-83
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
-0.170(11.1%) |
Mkt cap ! $232.5M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.48 | $1.36 | $632.2K | 451.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 4136 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |